Is NVS's Q1 2025 forecast achievable?

Novartis AG's Q1 2025 forecast is achievable, based on the following points:

1. Strong Financial Performance in Q1 2024: Novartis AG reported a net income of $2.69 billion for the first quarter of 2024, which is higher than the previous year's $2.29 billion. The basic earnings per share (EPS) were $1.31, up from $1.09 in the prior year. This indicates a robust financial performance that bodes well for the company's forecasted performance in Q1 2025.
2. Revenue Growth and Beat of Estimates: The company's revenue for Q1 2024 was $11.83 billion, which beat consensus expectations. This demonstrates Novartis AG's ability to exceed market expectations, a positive indicator for their forecasted performance.
3. Full-Year Guidance Raise: Novartis AG has raised its full-year guidance after Q1 performance, indicating confidence in its ability to meet financial targets for the year. This raises the likelihood that the Q1 2025 forecast will also be met.
4. Historical Performance and Market Position: Novartis AG has a strong market position and a history of solid financial performance. Their core operating income margin was 34.1% in Q1 2023, which is a strong indicator of the company's profitability. This historical performance supports the achievability of the Q1 2025 forecast.

In conclusion, considering Novartis AG's strong financial performance, revenue growth, guidance raise, and historical performance, the Q1 2025 forecast is achievable.